1. Enliven granted 875,000 stock options to CEO Richard Fair. 2. Options have an exercise price of $18.77, equal to closing stock price. 3. Options vest over time, potentially impacting long-term incentives. 4. Inducement aligns with Nasdaq regulations for executive grants. 5. Enliven focuses on precision oncology and developing therapeutics.
FAQ
Why Bullish?
The inducement stock options for leadership can signal growth potential. History shows that management incentives often correlate with stock performance.
How important is it?
The article signifies a strategic executive decision that can influence future corporate direction and investor sentiment.
Why Long Term?
The vesting schedule ties executive compensation to future performance, promoting sustained growth. Similar incentivization led to positive long-term results in other biotech firms.
BOULDER, Colo., Dec. 11, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. ("Enliven"), (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that on December 11, 2025, Enliven granted an inducement stock option to purchase 875,000 shares of Enliven's common stock to Richard Fair, Enliven's President and Chief Executive Officer and member of the board of directors, in connection with the commencement of Richard Fair's employment.
The inducement stock option has an exercise price of $18.77 per share, which is equal to the closing price of a share of Enliven's common stock on the grant date, and shall vest as follows: 25% of the shares subject to the inducement stock option shall vest on the one year anniversary of December 11, 2025, and an additional one forty-eighth (1/48th) of the shares subject to the inducement stock option shall vest monthly thereafter, subject to continued service through each vesting date.
The inducement award is subject to the terms of the Enliven Therapeutics, Inc. 2025 Inducement Equity Incentive Plan and related form of option agreement, and was granted as an inducement material to Mr. Fair to enter into employment with Enliven in accordance with Nasdaq Listing Rule 5635(c)(4).
About Enliven Therapeutics
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Boulder, Colorado.
View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-reports-inducement-grants-as-permitted-by-the-nasdaq-listing-rules-302639654.html
SOURCE Enliven Therapeutics, Inc.